We are live on ! Find out more
HARP

Harpoon Therapeutics, Inc. Common Stock
HARP

Delisted

HARP was delisted on the 8th of March, 2024.

Back to rankings

53 hedge funds and large institutions have $223M invested in Harpoon Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

6% more funds holding

Funds holding: 50 → 53 (+3)

20% less capital invested

Capital invested by funds: $279M → $223M (-$55.3M)

Holders
53
Holders Change
+3
Holders Change %
+6%
% of All Funds
1.17%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
12
Increased
22
Reduced
9
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$4.92M
2
SCM
Soleus Capital Management
Connecticut
+$4.89M
3
BlackRock
BlackRock
New York
+$4.87M
4
DM
Deerfield Management
New York
+$2.36M
5
DCM
DAFNA Capital Management
California
+$2.07M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$13.4M
2
SFM
Sphera Funds Management
Israel
-$5.68M
3
BFM
Boothbay Fund Management
New York
-$503K
4
CIBC World Market
CIBC World Market
Ontario, Canada
-$444K
5
OAM
Oxford Asset Management
United Kingdom
-$297K
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
1
MPM Asset Management
Massachusetts
$52.4M – – –
MB
2
MPM BioImpact
Massachusetts
$45.1M – – –
NLVP
3
New Leaf Venture Partners
New York
$33.8M – – –
O
4
OrbiMed
New York
$28.3M – – –
AG
5
Artal Group
Luxembourg
$13.9M +$4.92M +35,000 +41%
BlackRock
6
BlackRock
New York
$9.3M +$4.87M +34,664 +76%
CAM
7
Cormorant Asset Management
Massachusetts
$7.53M – – –
SCM
8
Soleus Capital Management
Connecticut
$5.45M +$4.89M +34,773 +282%
Vanguard Group
9
Vanguard Group
Pennsylvania
$4.67M +$181K +1,288 +3%
BBA
10
Baker Bros. Advisors
New York
$2.37M -$138K -982 -5%
FI
11
Fosun International
China
$2.21M – – –
DM
12
Deerfield Management
New York
$1.94M +$2.36M +16,764 New
DCM
13
DAFNA Capital Management
California
$1.71M +$2.07M +14,747 New
N
14
Nuveen
North Carolina
$1.69M +$1.83M +13,048 +828%
State Street
15
State Street
Massachusetts
$1.69M +$305K +2,172 +18%
B
16
Bailard
California
$1.34M +$1.62M +11,550 New
Renaissance Technologies
17
Renaissance Technologies
New York
$1.32M +$23.9K +170 +2%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.15M +$170K +1,210 +14%
Northern Trust
19
Northern Trust
Illinois
$1.04M +$136K +969 +12%
Millennium Management
20
Millennium Management
New York
$949K +$12.9K +92 +1%
WP
21
Woodline Partners
California
$914K +$1.11M +7,894 New
Squarepoint
22
Squarepoint
New York
$783K +$482K +3,431 +103%
Charles Schwab
23
Charles Schwab
California
$530K +$8.15K +58 +1%
Two Sigma Investments
24
Two Sigma Investments
New York
$466K +$9.56K +68 +2%
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$340K +$413K +2,935 New
1
2 3

HARP Hedge Fund Activity: Q1 2020 in Review

53 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q1 2020, worth a combined $223M — down 20% from $279M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new HARP positions and 9 closed out — a net gain of 3 holders — while 22 added to existing stakes and 9 trimmed.

The largest buyer was Artal Group, adding an estimated $4.92M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.4M sold.

  • 53 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q1 2020, up from 50 in Q4 2019.
  • Funds reported $223M of Harpoon Therapeutics, Inc. Common Stock stock for Q1 2020, down 20% quarter-over-quarter.
  • 12 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q1 2020 and 9 closed out, a net change of +3 holders.
  • The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q1 2020 was Artal Group, an estimated $4.92M added.
  • The largest Harpoon Therapeutics, Inc. Common Stock seller in Q1 2020 was EcoR1 Capital, an estimated $13.4M sold.

Based on aggregated 13F filings for Q1 2020.